Eli Lilly's Olomorasib Receives FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, an investigational KRAS G12C inhibitor, as a monotherapy for adult patients with advanced pancreatic cancer who have a KRAS G12C mutation and have received at least one prior systemic therapy. This designation aims to expedite the development and review of drugs for serious conditions where preliminary clinical evidence suggests substantial improvement over existing therapies.